Breaking Finance News

A statement released earlier today by National Bank Financial about Theratechnologies Inc. (TSE:TH) bumps down the target price to $8.75

Stating a potential upside of 0.30%, National Bank Financial dropped the price target of Theratechnologies Inc. (TSE:TH) to $8.75

Previously on Friday October 06, 2017, National Bank Financial reported about Theratechnologies Inc. (TSE:TH) raised the target price from $9.25 to $9.75. At the time, this indicated a possible upside of 0.23%.

Yesterday Theratechnologies Inc. (TSE:TH) traded 1.29% higher at $6.73. Theratechnologies Inc.’s 50-day moving average is $7.54 and its 200-day moving average is $7.16. The last stock price is down 9.72% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 148,769 shares of TH traded hands, up from an average trading volume of 109,633

Recent Performance Chart

Theratechnologies Inc. (TSE:TH)

Theratechnologies Inc. has 52 week low of $2.61 and a 52 week high of $8.72 and has a market capitalization of $0.

In addition to National Bank Financial reporting its stock price target, a total of 5 brokerages have issued a ratings update on the company. The average stock price target is $3.88 with 2 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Theratechnologies Inc. (TSE:TH)

Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *